

Global Cosentyx drug Market Forecast: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

LONDON, GREATER LONDON , UNITED KINGDOM, January 20, 2025 /EINPresswire.com/ -- The <u>global Cosentyx drug market</u> is poised for significant growth with long-term benefits predicted. The market size for Cosentyx has marked notable strides in recent years, growing from \$5,195.11 million in 2024 to a projected \$5,683.20 million in 2025, reflecting a robust compound annual growth rate CAGR of 9.4%. The growth in this period owes much to factors like the FDA approval and early market entry of Cosentyx, its clinical efficacy and safety profile, the global shift toward biologics, real-world data, and global regulatory approvals.

Can the Cosentyx Drug Market Continue Its Momentum?

Looking ahead, the Cosentyx drug market stands to see impressive growth. It is projected to expand to \$8,030.80 million by 2029, reflecting a compound annual growth rate CAGR of 9.0%. This anticipated growth in the forecast period is attributed to the increasing prevalence of autoimmune diseases, expansion of approved indications, advancements in biologic therapies, favorable reimbursement policies, and strong clinical outcomes. The forecast period will likely see trends like expanding applications for autoimmune diseases, a shift toward personalized medicine, and the dominance of subcutaneous administration and R&D in new therapeutic areas.

Get Your Free Sample of The Cosentyx Drug Market Report: <u>https://www.thebusinessresearchcompany.com/sample_request?id=19891&type=smp</u>

How Are Autoimmune Diseases Driving the Cosentyx Market?

The rising prevalence of autoimmune diseases is anticipated to fuel the future growth of the Cosentyx market. Autoimmune diseases are disorders where the immune system mistakenly targets the body's healthy cells and tissues. Genetic predisposition, environmental factors like infections and pollutants, and lifestyle changes, including increased stress and dietary shifts, are implicated in the escalating prevalence of these diseases. Cosentyx secukinumab offers a promising solution by targeting and inhibiting interleukin-17A, a critical cytokine involved in the inflammatory process, thereby alleviating symptoms, improving the quality of life, and effectively managing conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis.

How Does Rising Healthcare Expenditure Influence the Cosentyx Drug Market? Another significant driver of the Cosentyx market is the increase in healthcare expenditure. This term encapsulates the total spend on healthcare goods and services, personal health care, preventive services, and public health activities, all targeted at improving health outcomes over a set period. Rising healthcare expenditure is influenced by an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services.

Healthcare expenditure for Cosentyx is primarily directed toward managing moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, thereby improving patient outcomes through targeted biologic therapy. For instance, according to a report published in May 2024 by the Office For National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, outpacing the growth rate of 0.9% seen in 2022. Therefore, the escalating healthcare expenditure provides a substantial impetus for the Cosentyx market.

Order Your Report Now For A Swift Delivery: <u>https://www.thebusinessresearchcompany.com/report/cosentyx-drug-global-market-report</u>

Who Are the Key Industry Players in the Cosentyx Drug Market? Major companies operating in the Cosentyx drug market include Novartis AG, a pharmaceutical giant known for its innovations and significant contribution to the healthcare industry.

What Are the Emerging Trends in the Cosentyx Drug Market?

Key trends in the Cosentyx drug market include a focus on developing advanced therapies like biological treatment options to address unmet medical needs, enhance treatment efficacy, and provide targeted therapies for managing chronic autoimmune conditions. These measures aim to cement market positions and cater to a growing patient population. Biologic treatments are advanced therapies derived from living organisms or their cells that specifically target components of the immune system to effectively treat autoimmune conditions.

How Is the <u>Cosentyx Drug Market Segmented</u>? The Cosentyx drug market can be segmented as follows:

1 By Indication: Hidradenitis suppurativa; Psoriatic arthritis; Ankylosing spondylitis; Plaque Psoriasis

2 By Route Of Administration: Subcutaneous injection; Intravenous infusion

3 By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies

What Are the Regional Insights Into the Cosentyx Drug Market?

In 2024, North America was the largest region in the Cosentyx drug market. However, Asia-Pacific is projected to be the fastest growing region in the forecast period. The report encapsulates insights into regions like Asia-Pacific, Western Europe, Eastern Europe, North America, South

America, Middle East, and Africa.

Browse more similar reports-Osteoarthritis Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report</u> Rheumatoid Arthritis Drugs Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report</u> Arthritis Monoclonal Antibodies Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report</u>

About The Business Research Company

The Business Research Company, renowned for comprehensive, data-rich research and insights, offers over 15000+ reports across 27 industries, spanning 60+ geographies. With 1,500,000 datasets, our rich resources, in-depth secondary research, and unique insights from industry leaders ensure you have the information you need to stay ahead in the game.

Contact us at: The Business Research Company: link<u>https://www.thebusinessresearchcompany.com/</u> Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708

Email us at info@tbrc.info

Follow us on: LinkedIn: <u>https://in.linkedin.com/company/the-business-research-company</u> YouTube: ttps://<u>www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ</u> Global Market Model: <u>https://www.thebusinessresearchcompany.com/global-market-model</u>

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook X LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/778524350

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.